Principal Financial Group Inc. Has $33.16 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Principal Financial Group Inc. boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 841,011 shares of the biopharmaceutical company's stock after acquiring an additional 10,827 shares during the period. Principal Financial Group Inc. owned 0.53% of TG Therapeutics worth $33,161,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $14,508,000. Charles Schwab Investment Management Inc. increased its stake in TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after acquiring an additional 84,904 shares during the period. Norges Bank bought a new stake in TG Therapeutics in the fourth quarter valued at about $12,085,000. Allspring Global Investments Holdings LLC increased its stake in TG Therapeutics by 54.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock valued at $898,000 after acquiring an additional 8,338 shares during the period. Finally, New York State Teachers Retirement System increased its stake in TG Therapeutics by 175.0% in the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock valued at $4,746,000 after acquiring an additional 76,600 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group initiated coverage on shares of TG Therapeutics in a research note on Thursday. They set a "neutral" rating and a $37.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.80.

TG Therapeutics Stock Down 0.8%

Shares of TGTX stock traded down $0.32 during trading hours on Thursday, hitting $37.61. 642,788 shares of the company were exchanged, compared to its average volume of 2,886,872. The business has a 50 day moving average of $36.33 and a two-hundred day moving average of $35.21. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. TG Therapeutics, Inc. has a 52 week low of $16.65 and a 52 week high of $46.48. The company has a market capitalization of $5.97 billion, a PE ratio of 156.73 and a beta of 1.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business's revenue was up 90.4% on a year-over-year basis. During the same period last year, the business earned ($0.07) EPS. Analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director owned 228,816 shares in the company, valued at $8,452,463.04. The trade was a 4.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.64% of the stock is owned by company insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.